NICE’s Nod To Arzerra In CLL A Prelude To Rivalry With Gazyvaro, MabThera
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.’s NICE has given the nod to GSK’s Arzerra (ofatumumab) for first-line CLL, making an eventual rivalry with Roche’s Gazyvaro and potentially revived MabThera a possibility.
You may also be interested in...
GlaxoSmithKline’s Arzerra Gets Better CLL Label, But Now Faces Competition With Gazyva
GlaxoSmithKline exec Klaus Edvardsen says the new label should give drug a boost, as previous indication was very restrictive. Approved in 2009, Arzerra had just £75 million in 2013 worldwide sales.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.